Literature DB >> 34782352

Acute-to-Chronic Glycemic Ratio as a Predictor of COVID-19 Severity and Mortality.

Jordi Ramon1, Gemma Llauradó1,2,3,4, Roberto Güerri2,3,5, Elisenda Climent1,2,3, Silvia Ballesta1,2, David Benaiges1,2,3, Inmaculada López-Montesinos2,5, Humberto Navarro1,3, Natalia Fernández1, Maria José Carrera1,3, Dídac Mauricio4,6,7, Juana A Flores-Le Roux1,2,3, Juan-José Chillarón1,2,3.   

Abstract

OBJECTIVE: To evaluate the association between acute-to-chronic (A/C) glycemic ratio and mortality and severity outcomes for patients with type 2 diabetes (T2D) hospitalized with coronavirus disease 2019 (COVID-19). RESEARCH DESIGN AND METHODS: A total of 91 patients were included. We measured glycemia at admission and estimated the average chronic glucose levels to calculate the A/C glycemic ratio. The primary outcome was a composite of in-hospital mortality, intensive care unit admission, and mechanical ventilation.
RESULTS: Thirty-five patients had a primary outcome event, presenting a significant association with the A/C glycemic ratio (hazard ratio [HR] 1.57 [95% CI 1.14-2.15], P = 0.005). In comparisons with the 2nd tertile, the 3rd tertile of the A/C glycemic ratio was associated with the primary outcome (HR 3.39 [95% CI 1.31-8.75], P = 0.012). In the multivariate analysis, after additional adjustment for age, sex, comorbidities, inflammatory markers, and corticosteroid therapy, the association for the 3rd tertile (HR 3.96 [95% CI 1.35-11.59], P = 0.012) remained significant.
CONCLUSIONS: In patients with T2D hospitalized with COVID-19, the imbalance between acute glycemia at admission and chronic metabolic control is associated with worse prognosis.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2022        PMID: 34782352     DOI: 10.2337/dc21-1321

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  4 in total

1.  Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Heart Failure: A Prospective Study.

Authors:  Mª José Carrera; Pedro Moliner; Gemma Llauradó; Cristina Enjuanes; Laura Conangla; Juan-José Chillarón; Silvia Ballesta; Elisenda Climent; Josep Comín-Colet; Juana-Antonia Flores-Le Roux
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

2.  Glucometabolic changes influence hospitalization and outcome in patients with COVID-19: An observational cohort study.

Authors:  Clara L Clausen; Christian Leo-Hansen; Daniel Faurholt-Jepsen; Rikke Krogh-Madsen; Christian Ritz; Ole Kirk; Henrik L Jørgensen; Thomas Benfield; Thomas P Almdal; Ole Snorgaard
Journal:  Diabetes Res Clin Pract       Date:  2022-04-25       Impact factor: 8.180

3.  Stress Hyperglycemia Ratio as a Prognostic Marker in Diabetic Patients Hospitalized with COVID-19.

Authors:  Mohamed Aon; Abdullah Alsaeedi; Azeez Alzafiri; Abdelrahman Al-Shammari; Sherif Taha; Omar Al-Shammari; Mahmoud Tawakul; Jarrah Alshammari; Naser Alherz; Monerah Alenezi; Meshari Eyadah; Mariam Aldhafeeri; Teflah Alharbi; Duaa Alshammari; Zaid Alenezi; Salem Aldouseri; Ebraheem Albazee; Mohamed M Ibrahim; Ahmed H Aoun
Journal:  Infect Dis Rep       Date:  2022-09-07

4.  Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Authors:  Olivier Deckmyn; Thierry Poynard; Pierre Bedossa; Valérie Paradis; Valentina Peta; Raluca Pais; Vlad Ratziu; Dominique Thabut; Angelique Brzustowski; Jean-François Gautier; Patrice Cacoub; Dominique Valla
Journal:  Biomedicines       Date:  2022-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.